Effect of ulinastatin combined with thymosin alpha1 on sepsis: A systematic review and meta-analysis of Chinese and Indian patients

Journal of Critical Care

Volumn 39, Issue , 2017, Pages 259-266

  Liu, Dadong ^a   Yu, Zongying ^b   Yin, Jiangtao ^a   Chen, Yikun ^a   Zhang, Hao ^a   Xin, Fan ^a   Fu, Haiyan ^a   Wan, Bing ^a  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b Zhenjiang Fourth People's Hospital   (China)

Author keywords

Meta analysis; Sepsis; Ulinastatin

Indexed keywords

HYPERTENSIVE FACTOR; INTERLEUKIN 10; INTERLEUKIN 6; THYMOSIN ALPHA1; TUMOR NECROSIS FACTOR; ULINASTATIN; GLYCOPROTEIN; IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; THYMOSIN;

APACHE; CHINESE; COMBINATION DRUG THERAPY; CYTOKINE PRODUCTION; DISEASE DURATION; DRUG EFFECT; DRUG USE; HUMAN; INDIAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MECHANICAL VENTILATOR; META ANALYSIS; MORTALITY RATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SYSTEMATIC REVIEW; ADULT; ANALOGS AND DERIVATIVES; ARTIFICIAL VENTILATION; CHINA; INDIA; INFLAMMATION; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; SEVERITY OF ILLNESS INDEX; SOFTWARE; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; CHINA; GLYCOPROTEINS; HUMANS; INDIA; INFLAMMATION; INTENSIVE CARE UNITS; INTERLEUKIN-10; INTERLEUKIN-6; LENGTH OF STAY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RESPIRATION, ARTIFICIAL; SEPSIS; SEVERITY OF ILLNESS INDEX; SOFTWARE; SURVIVAL RATE; THYMOSIN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85008655979     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2016.12.013     Document Type: Review

References (51)

1. [1] Angus, D.C., van der Poll, T., Severe sepsis and septic shock. N Engl J Med, 369, 2013, 2063.
2. [2] Levy, M.M., Dellinger, R.P., Townsend, S.R., Linde-Zwirble, W.T., Marshall, J.C., Bion, J., et al. The surviving sepsis campaign: results of an international guideline–based performance improvement program targeting severe sepsis. Crit Care Med 38 (2010), 367–374.
3. [3] Dellinger, R.P., Levy, M.M., Rhodes, A., Annane, D., Gerlach, H., Opal, S.M., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41 (2013), 580–637.
4. [4] Remick, D.G., Pathophysiology of sepsis. Am J Pathol 170 (2007), 1435–1444.
5. [5] Hotchkiss, R.S., Opal, S., Immunotherapy for sepsis—a new approach against an ancient foe. N Engl J Med 363 (2010), 87–89.
6. [6] Ferrer, R., Artigas, A., Suarez, D., Palencia, E., Levy, M.M., Arenzana, A., et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 180 (2009), 861–866.
7. [7] Zhang, Y., Zeng, Z., Cao, Y., Du, X., Wan, Z., Effect of urinary protease inhibitor (ulinastatin) on cardiopulmonary bypass: a meta-analysis for China and Japan. PLoS One, 9, 2014, e113973.
8. [8] Linder, A., Russell, J.A., An exciting candidate therapy for sepsis: ulinastatin, a urinary protease inhibitor. Intensive Care Med 40 (2014), 1164–1167.
9. [9] Uemura, K., Murakami, Y., Hayashidani, Y., Sudo, T., Hashimoto, Y., Ohge, H., et al. Randomized clinical trial to assess the efficacy of ulinastatin for postoperative pancreatitis following pancreaticoduodenectomy. J Surg Oncol 98 (2008), 309–313.
10. [10] Kanai, T., Ishiwata, T., Kobayashi, T., Sato, H., Takizawa, M., Kawamura, Y., et al. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study. Circulation 124 (2011), 2822–2828.
11. [11] Inoue, K., Takano, H., Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders. Expert Opin Investig Drugs 19 (2010), 513–520.
12. [12] Leng, Y.X., Yang, S.G., Song, Y.H., Zhu, X., Yao, G.Q., Ulinastatin for acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. World J Crit Care Med 3 (2014), 34–41.
13. [13] Jiang, L., Yang, L., Zhang, M., Fang, X., Huang, Z., Yang, Z., et al. Beneficial effects of ulinastatin on gut barrier function in sepsis. Indian J Med Res 138 (2013), 904–911.
14. [14] McClure, J.E., Lameris, N., Wara, D.W., Goldstein, A.L., Immunochemical studies on thymosin: radioimmunoassay of thymosin alpha 1. J Immunol 128 (1982), 368–375.
15. [15] Goldstein, A.L., Goldstein, A.L., From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther 9 (2009), 593–608.
16. [16] Tuthill, C., Rios, I., De Rosa, A., Camerini, R., Thymosin alpha1 continues to show promise as an enhancer for vaccine response. Ann N Y Acad Sci 1270 (2012), 21–27.
17. [17] Ciancio, A., Rizzetto, M., Thymalfasin in the treatment of hepatitis B and C. Ann N Y Acad Sci 1194 (2010), 141–146.
18. [18] Maio, M., Mackiewicz, A., Testori, A., Trefzer, U., Ferraresi, V., Jassem, J., et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol 28 (2010), 1780–1787.
19. [19] Garaci, E., Pica, F., Serafino, A., Balestrieri, E., Matteucci, C., Moroni, G., et al. Thymosin alpha1 and cancer: action on immune effector and tumor target cells. Ann N Y Acad Sci 1269 (2012), 26–33.
20. [20] Wan, J., Shan, Y., Shan, H., Li, G., Wang, T., Guan, J., et al. Thymosin-alpha1 promotes the apoptosis of regulatory T cells and survival rate in septic mice. Front Biosci (Landmark Ed) 16 (2011), 3004–3013.
21. [21] Zhang, D., Zhou, Y., Cheng, Q., Effects of combined thymosin and hydrocortisone on immune response in septic mice. Int J Clin Exp Med 8 (2015), 12989–12994.
22. [22] Wu, J., Zhou, L., Liu, J., Ma, G., Kou, Q., He, Z., et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care, 17, 2013, R8.
23. [23] Liu, F., Wang, H.M., Wang, T., Zhang, Y.M., Zhu, X., The efficacy of thymosin alpha1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials. BMC Infect Dis, 16, 2016, 488.
24. [24] Feng, L.Z.Z.Q., Meta-analysis of the efficacy of the septic shock by therapy of ulinastatin. Chin J Clinicans (Electronic Edition) 7 (2013), 904–911.
25. [25] Zhou, G.S.H.B., Ye, L.J., Zhang, L., Ma, L.X., Gao, L., Yao, G.H., et al. Meta-analysis of the efficacy of the septis by treatment of xuebijin combined with ulinastatin. J Guangdong Med Coll 32 (2014), 626–628.
26. [26] Yang, G.D.A., Li, J., Zhang, J., Zhang, M.Z., Meta-analysis of the clinical efficacy of the septis by treatment of ulinastatin. Zhejiang J Clin Med 15 (2013), 197–199.
27. [27] Saigal, S., Kapoor, G., Ulinastatin: is it worth using in severe sepsis?. Intensive Care Med, 40, 2014, 1185.
28. [28] Karnad, D.R., Bhadade, R., Verma, P.K., Moulick, N.D., Daga, M.K., Chafekar, N.D., et al. Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med 40 (2014), 830–838.
29. [29] Feng, Z., Shi, Q., Fan, Y., Wang, Q., Yin, W., Ulinastatin and/or thymosin alpha1 for severe sepsis: a systematic review and meta-analysis. J Trauma Acute Care Surg 80 (2016), 335–340.
30. [30] Wang, F.Y., Fang, B., Qiang, X.H., Yu, T.O., Zhong, J.R., Cao, J., et al. The efficacy and immunomodulatory effects of ulinastatin and thymosin alpha1 for sepsis: a systematic review and meta-analysis. Biomed Res Int, 2016, 2016, 9508493.
31. [31] Han, D., Shang, W., Wang, G., Sun, L., Zhang, Y., Wen, H., et al. Ulinastatin- and thymosin alpha1–based immunomodulatory strategy for sepsis: a meta-analysis. Int Immunopharmacol 29 (2015), 377–382.
32. [32] Li, C., Bo, L., Liu, Q., Jin, F., Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis. Int J Infect Dis 33 (2015), 90–96.
33. [33] Bone, R.C., Balk, R.A., Cerra, F.B., Dellinger, R.P., Fein, A.M., Knaus, W.A., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101 (1992), 1644–1655.
34. [34] Levy, M.M., Fink, M.P., Marshall, J.C., Abraham, E., Angus, D., Cook, D., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29 (2003), 530–538.
35. [35] Knaus, W.A., Draper, E.A., Wagner, D.P., Zimmerman, J.E., APACHE II: a severity of disease classification system. Crit Care Med 13 (1985), 818–829.
36. [36] Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J., Gavaghan, D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996), 1–12.
37. [37] Wu, T.J., Zhang, L.N., Kang, C.C., The effect of ulinastatin on disbalance of inflammation and immune status in patients with severe sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 25 (2013), 219–223.
38. [38] Su, L., Meng, F.S., Tang, Y.Q., Wen, Q., Liu, Y.S., Tang, L.Q., et al. Clinical effects of ulinastatin and thymosin alpha1 on immune-modulation in septic patients. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 21 (2009), 147–150.
39. [39] Huang, S.W., Chen, J., Ouyang, B., Yang, C.H., Chen, M.Y., Guan, X.D., Immunotherapy improves immune homeostasis and increases survival rate of septic patients. Chin J Traumatol 12 (2009), 344–349.
40. [40] Li, Y., Chen, H., Li, X., Zhou, W., He, M., Chiriva-Internati, M., et al. A new immunomodulatory therapy for severe sepsis: ulinastatin plus thymosin {alpha} 1. J Intensive Care Med 24 (2009), 47–53.
41. [41] Chen, H., He, M.Y., Li, Y.M., Treatment of patients with severe sepsis using ulinastatin and thymosin alpha1: a prospective, randomized, controlled pilot study. Chin Med J (Engl) 122 (2009), 883–888.
42. [42] Zhang, Y., Chen, H., Li, Y.M., Zheng, S.S., Chen, Y.G., Li, L.J., et al. Thymosin alpha1– and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria. J Infect Dis 198 (2008), 723–730.
43. [43] Cooperative Group of Immunomodulatory Therapy of Sepsis, Lin, H.Y., Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with ulinastatin and maipuxin. Zhonghua Yi Xue Za Zhi 87 (2007), 451–457.
44. [44] Higgins, J.P., Altman, D.G., Gotzsche, P.C., Juni, P., Moher, D., Oxman, A.D., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
45. [45] Prashant, A., Vishwanath, P., Kulkarni, P., Sathya Narayana, P., Gowdara, V., Nataraj, S.M., et al. Comparative assessment of cytokines and other inflammatory markers for the early diagnosis of neonatal sepsis—a case control study. PLoS One, 8, 2013, e68426.
46. [46] Suarez-Santamaria, M., Santolaria, F., Perez-Ramirez, A., Aleman-Valls, M.R., Martinez-Riera, A., Gonzalez-Reimers, E., et al. Prognostic value of inflammatory markers (notably cytokines and procalcitonin), nutritional assessment, and organ function in patients with sepsis. Eur Cytokine Netw 21 (2010), 19–26.
47. [47] Boomer, J.S., To, K., Chang, K.C., Takasu, O., Osborne, D.F., Walton, A.H., et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306 (2011), 2594–2605.
48. [48] Hotchkiss, R.S., Monneret, G., Payen, D., Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 13 (2013), 260–268.
49. [49] Venet, F., Foray, A.P., Villars-Mechin, A., Malcus, C., Poitevin-Later, F., Lepape, A., et al. IL-7 restores lymphocyte functions in septic patients. J Immunol 189 (2012), 5073–5081.
50. [50] Inoue, K., Takano, H., Yanagisawa, R., Yoshikawa, T., Protective effects of urinary trypsin inhibitor on systemic inflammatory response induced by lipopolysaccharide. J Clin Biochem Nutr 43 (2008), 139–142.
51. [51] Rupesh, K.R., Priya, A.M., Sundarakrishnan, B., Venkatesan, R., Lakshmi, B.S., Jayachandran, S., 2,2′-Bipyridyl based copper complexes down regulate expression of pro-inflammatory cytokines and suppress MAPKs in mitogen induced peripheral blood mononuclear cells. Eur J Med Chem 45 (2010), 2141–2146.